US7135584B2
(en)
|
1995-08-07 |
2006-11-14 |
Wake Forest University |
Lipid analogs for treating viral infections
|
DE69535758D1
(de)
|
1994-08-29 |
2008-07-03 |
Univ Wake Forest |
Lipid-analoge zur behandlung von viralen infektionen
|
JP4080541B2
(ja)
*
|
1996-10-18 |
2008-04-23 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子
|
GB9707659D0
(en)
*
|
1997-04-16 |
1997-06-04 |
Peptide Therapeutics Ltd |
Hepatitis C NS3 Protease inhibitors
|
US6767991B1
(en)
|
1997-08-11 |
2004-07-27 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis C inhibitor peptides
|
NZ503263A
(en)
*
|
1997-08-11 |
2002-10-25 |
Boehringer Ingelheim Ca Ltd |
Hepatitis C NS3 protease inhibitor peptides and peptide analogues
|
JP4354632B2
(ja)
*
|
1997-08-11 |
2009-10-28 |
ベーリンガー インゲルハイム (カナダ) リミテッド |
C型肝炎抑制剤ペプチド
|
GB9806815D0
(en)
*
|
1998-03-30 |
1998-05-27 |
Hoffmann La Roche |
Amino acid derivatives
|
DE69934104T2
(de)
*
|
1998-03-31 |
2007-06-28 |
Vertex Pharmaceuticals Inc., Cambridge |
Inhibitoren von serinproteasen, insbesondere von hepatitis c virus ns3 protease
|
GB9809664D0
(en)
*
|
1998-05-06 |
1998-07-01 |
Hoffmann La Roche |
a-Ketoamide derivatives
|
GB9812523D0
(en)
|
1998-06-10 |
1998-08-05 |
Angeletti P Ist Richerche Bio |
Peptide inhibitors of hepatitis c virus ns3 protease
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
AR022061A1
(es)
*
|
1998-08-10 |
2002-09-04 |
Boehringer Ingelheim Ca Ltd |
Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
|
EP1159273A1
(en)
|
1999-03-02 |
2001-12-05 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Compounds useful as reversible inhibitors of cathepsin s
|
UA74546C2
(en)
*
|
1999-04-06 |
2006-01-16 |
Boehringer Ingelheim Ca Ltd |
Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
|
US6608027B1
(en)
|
1999-04-06 |
2003-08-19 |
Boehringer Ingelheim (Canada) Ltd |
Macrocyclic peptides active against the hepatitis C virus
|
AU5788800A
(en)
*
|
1999-07-07 |
2001-01-22 |
Du Pont Pharmaceuticals Company |
Peptide boronic acid inhibitors of hepatitis c virus protease
|
WO2001007407A1
(en)
*
|
1999-07-26 |
2001-02-01 |
Bristol-Myers Squibb Pharma Company |
Lactam inhibitors of hepatitis c virus ns3 protease
|
US7122627B2
(en)
|
1999-07-26 |
2006-10-17 |
Bristol-Myers Squibb Company |
Lactam inhibitors of Hepatitis C virus NS3 protease
|
US6420364B1
(en)
|
1999-09-13 |
2002-07-16 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compound useful as reversible inhibitors of cysteine proteases
|
US7026469B2
(en)
|
2000-10-19 |
2006-04-11 |
Wake Forest University School Of Medicine |
Compositions and methods of double-targeting virus infections and cancer cells
|
WO2001040262A1
(en)
*
|
1999-12-03 |
2001-06-07 |
Bristol-Myers Squibb Pharma Company |
Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
|
US7238709B2
(en)
*
|
1999-12-07 |
2007-07-03 |
Theravance, Inc. |
Therapeutic carbamates
|
JP2003525294A
(ja)
|
2000-02-29 |
2003-08-26 |
ブリストル−マイヤーズ スクイブ ファーマ カンパニー |
C型肝炎ウイルスns3プロテアーゼの阻害剤
|
ES2240446T3
(es)
|
2000-04-03 |
2005-10-16 |
Vertex Pharma |
Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
|
AU2006202124B2
(en)
*
|
2000-04-03 |
2010-01-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of Serine Proteases, Particularly Hepatitis C Virus NS3 Protease
|
KR20030036152A
(ko)
|
2000-04-05 |
2003-05-09 |
쉐링 코포레이션 |
N-사이클릭 p2 잔기를 포함하는 c형 간염 바이러스의매크로사이클릭 ns3-세린 프로테아제 억제제
|
CN1935833A
(zh)
|
2000-04-19 |
2007-03-28 |
先灵公司 |
含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂
|
PE20011350A1
(es)
|
2000-05-19 |
2002-01-15 |
Vertex Pharma |
PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
EP1294735A2
(en)
|
2000-05-26 |
2003-03-26 |
Novirio Pharmaceuticals Limited |
Methods and compositions for treating flaviviruses and pestiviruses
|
US20020007324A1
(en)
*
|
2000-06-09 |
2002-01-17 |
Centner David J. |
System and method for effectively conducting transactions between buyers and suppliers
|
AR029851A1
(es)
*
|
2000-07-21 |
2003-07-16 |
Dendreon Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
|
US7012066B2
(en)
*
|
2000-07-21 |
2006-03-14 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
CZ2003195A3
(cs)
|
2000-07-21 |
2003-04-16 |
Schering Corporation |
Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostředek
|
AR034127A1
(es)
*
|
2000-07-21 |
2004-02-04 |
Schering Corp |
Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
|
US7244721B2
(en)
*
|
2000-07-21 |
2007-07-17 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
SV2003000617A
(es)
*
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
DK1326632T3
(da)
*
|
2000-10-12 |
2007-01-15 |
Viromics Gmbh |
Protease-inhibitorer til behandling af infektioner af hepatitisvirus
|
AU2874902A
(en)
|
2000-10-18 |
2002-04-29 |
Pharmasset Ltd |
Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
|
US7309696B2
(en)
|
2000-10-19 |
2007-12-18 |
Wake Forest University |
Compositions and methods for targeting cancer cells
|
US6846806B2
(en)
|
2000-10-23 |
2005-01-25 |
Bristol-Myers Squibb Company |
Peptide inhibitors of Hepatitis C virus NS3 protein
|
ATE430166T1
(de)
*
|
2000-12-12 |
2009-05-15 |
Schering Corp |
Diarylrest entfassende peptide als inhibitoren des ns-3 serinproteases von hepatitis c virus
|
US6727366B2
(en)
|
2000-12-13 |
2004-04-27 |
Bristol-Myers Squibb Pharma Company |
Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
|
US6653295B2
(en)
|
2000-12-13 |
2003-11-25 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus NS3 protease
|
ATE526339T1
(de)
|
2001-01-22 |
2011-10-15 |
Merck Sharp & Dohme |
Nukleosidderivate als inhibitoren der rna- abhängigen viralen rna-polymerase
|
CA2449504A1
(en)
|
2001-07-11 |
2003-01-23 |
Vertex Pharmaceuticals Incorporated |
Bridged bicyclic serine protease inhibitors
|
IL160080A0
(en)
|
2001-08-31 |
2004-06-20 |
Thomson Licensing Sa |
Sequence counter for an audio visual stream
|
AU2002330154A1
(en)
|
2001-09-28 |
2003-04-07 |
Centre National De La Recherche Scientifique |
Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
|
WO2003035060A1
(en)
*
|
2001-10-24 |
2003-05-01 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
|
MY151199A
(en)
*
|
2001-11-02 |
2014-04-30 |
Rigel Pharmaceuticals Inc |
Substituted diphenyl heterocycles useful for treating hcv infection
|
KR20040077767A
(ko)
|
2002-01-23 |
2004-09-06 |
쉐링 코포레이션 |
C형 간염 바이러스 감염 치료용 ns3-세린 프로테아제억제제로서의 프롤린 화합물
|
US7119072B2
(en)
|
2002-01-30 |
2006-10-10 |
Boehringer Ingelheim (Canada) Ltd. |
Macrocyclic peptides active against the hepatitis C virus
|
US7091184B2
(en)
|
2002-02-01 |
2006-08-15 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
RU2004133044A
(ru)
*
|
2002-04-11 |
2006-01-27 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Ингибиторы сериновых протеаз, в частности, протеазы ns3-ns4a hcv
|
WO2004043339A2
(en)
|
2002-05-20 |
2004-05-27 |
Bristol-Myers Squibb Company |
Substituted cycloalkyl p1' hepatitis c virus inhibitors
|
JP4312711B2
(ja)
|
2002-05-20 |
2009-08-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
ヘテロ環式スルホンアミドc型肝炎ウイルス阻害剤
|
JP4312718B2
(ja)
*
|
2002-05-20 |
2009-08-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
C型肝炎ウイルス阻害剤
|
MY140680A
(en)
*
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
JP2005533817A
(ja)
|
2002-06-28 |
2005-11-10 |
イデニクス(ケイマン)リミテツド |
フラビウィルス科ウィルス感染治療用の修飾2′および3′−ヌクレオシドプロドラッグ
|
AU2003277891A1
(en)
*
|
2002-09-23 |
2004-04-08 |
Medivir Ab |
Hcv ns-3 serine protease inhibitors
|
US20050075279A1
(en)
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
PL377342A1
(pl)
|
2002-11-15 |
2006-01-23 |
Idenix (Cayman) Limited |
Nukleozydy rozgałęzione w pozycji 2' oraz mutacja Flaviviridae
|
AU2011203054B2
(en)
*
|
2003-04-11 |
2012-04-26 |
Vertex Pharmaceuticals, Incorporated |
Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
|
ATE547412T1
(de)
*
|
2003-04-11 |
2012-03-15 |
Vertex Pharma |
Inhibitoren von serinproteasen, insbesondere hcv- ns3-ns4a-protease
|
EP1620412A2
(en)
|
2003-05-02 |
2006-02-01 |
Rigel Pharmaceuticals, Inc. |
Heterocyclic compounds and hydro isomers thereof
|
RS51294B
(sr)
|
2003-05-21 |
2010-12-31 |
Boehringer Ingelheim International Gmbh. |
Inhibitorna jedinjenja za hepatitis c
|
EP4032897B1
(en)
|
2003-05-30 |
2025-01-29 |
Gilead Pharmasset LLC |
Modified fluorinated nucleoside analogues
|
NZ544789A
(en)
*
|
2003-07-18 |
2010-01-29 |
Vertex Pharma |
Dithia-azaspiro-nonane and decane derivatives as inhibitors of serine proteases
|
DK1658302T3
(da)
|
2003-07-25 |
2010-11-22 |
Idenix Pharmaceuticals Inc |
Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C
|
US7576206B2
(en)
|
2003-08-14 |
2009-08-18 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7223745B2
(en)
|
2003-08-14 |
2007-05-29 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
JP4527722B2
(ja)
|
2003-08-26 |
2010-08-18 |
シェーリング コーポレイション |
C型肝炎ウイルスの新規のペプチド模倣性ns3−セリンプロテアーゼインヒビター
|
TWI359147B
(en)
*
|
2003-09-05 |
2012-03-01 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hcv n
|
AU2004274468B2
(en)
*
|
2003-09-18 |
2009-07-23 |
Vertex Pharmaceuticals, Incorporated |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
PE20050431A1
(es)
|
2003-09-22 |
2005-07-19 |
Boehringer Ingelheim Int |
Peptidos macrociclicos activos contra el virus de la hepatitis c
|
AR046166A1
(es)
|
2003-09-26 |
2005-11-30 |
Schering Corp |
Inhibidores macrociclicos de la serina proteasa ns3 del virus de la hepatitis c
|
AU2004282148A1
(en)
*
|
2003-10-10 |
2005-04-28 |
Vertex Pharmaceuticals Incoporated |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
US7365092B2
(en)
|
2003-10-10 |
2008-04-29 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
BRPI0415373A
(pt)
|
2003-10-14 |
2006-12-12 |
Intermune Inc |
ácidos carboxìlicos macrocìclicos e acilsulfonamidas como inibidores de replicação de hcv
|
JP4890254B2
(ja)
|
2003-10-27 |
2012-03-07 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Hcvns3−ns4aプロテアーゼ耐性突然変異体
|
EP1944042A1
(en)
|
2003-10-27 |
2008-07-16 |
Vertex Pharmceuticals Incorporated |
Combinations for HCV treatment
|
US8187874B2
(en)
|
2003-10-27 |
2012-05-29 |
Vertex Pharmaceuticals Incorporated |
Drug discovery method
|
US7132504B2
(en)
|
2003-11-12 |
2006-11-07 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7309708B2
(en)
|
2003-11-20 |
2007-12-18 |
Birstol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7253160B2
(en)
|
2003-11-20 |
2007-08-07 |
Schering Corporation |
Depeptidized inhibitors of hepatitis C virus NS3 protease
|
US7135462B2
(en)
|
2003-11-20 |
2006-11-14 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
CA2549851C
(en)
|
2004-01-21 |
2012-09-11 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis c virus
|
AU2005207815B2
(en)
*
|
2004-01-30 |
2011-08-04 |
Medivir Ab |
HCV NS-3 serine protease inhibitors
|
CN1938332B
(zh)
|
2004-02-04 |
2011-10-19 |
沃泰克斯药物股份有限公司 |
丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
|
WO2005080399A1
(ja)
|
2004-02-24 |
2005-09-01 |
Japan Tobacco Inc. |
4環縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての利用
|
US20070049593A1
(en)
|
2004-02-24 |
2007-03-01 |
Japan Tobacco Inc. |
Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
|
TWI314927B
(en)
|
2004-02-27 |
2009-09-21 |
Schering Corporatio |
Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
|
US7816326B2
(en)
|
2004-02-27 |
2010-10-19 |
Schering Corporation |
Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
|
ES2349328T3
(es)
|
2004-02-27 |
2010-12-30 |
Schering Corporation |
Nuevos compuestos como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
|
EP1730165A1
(en)
|
2004-02-27 |
2006-12-13 |
Schering Corporation |
Inhibitors of hepatitis c virus ns3 protease
|
RU2006134005A
(ru)
|
2004-02-27 |
2008-04-10 |
Шеринг Корпорейшн (US) |
Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
|
AU2005223767B2
(en)
*
|
2004-03-12 |
2011-12-01 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
|
US8198270B2
(en)
*
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
SG185306A1
(en)
|
2004-04-15 |
2012-11-29 |
Onyx Therapeutics Inc |
Compounds for proteasome enzyme inhibition
|
EP2564834A3
(en)
*
|
2004-05-10 |
2013-08-21 |
Onyx Therapeutics, Inc. |
Compounds for Proteasome Enzyme Inhibition
|
US7399749B2
(en)
|
2004-05-20 |
2008-07-15 |
Schering Corporation |
Substituted prolines as inhibitors of hepatitis C virus NS3 serine protease
|
CA2571984C
(en)
*
|
2004-07-16 |
2012-04-10 |
Gilead Sciences, Inc. |
Antiviral compounds
|
UY29016A1
(es)
|
2004-07-20 |
2006-02-24 |
Boehringer Ingelheim Int |
Analogos de dipeptidos inhibidores de la hepatitis c
|
JP4914355B2
(ja)
|
2004-07-20 |
2012-04-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
C型肝炎インヒビターペプチド類似体
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
WO2006020580A2
(en)
*
|
2004-08-09 |
2006-02-23 |
Alios Biopharma Inc. |
Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
MX2007002371A
(es)
|
2004-08-27 |
2007-04-23 |
Schering Corp |
Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
|
ES2769377T3
(es)
|
2004-09-14 |
2020-06-25 |
Gilead Pharmasset Llc |
Intermedios de D-ribonolactona con sustitución de 2-fluoro-2-alquilo
|
SG191661A1
(en)
|
2004-10-01 |
2013-07-31 |
Vertex Pharma |
Hcv ns3-ns4a protease inhibition
|
US7659263B2
(en)
|
2004-11-12 |
2010-02-09 |
Japan Tobacco Inc. |
Thienopyrrole compound and use thereof as HCV polymerase inhibitor
|
US7323447B2
(en)
|
2005-02-08 |
2008-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7468383B2
(en)
|
2005-02-11 |
2008-12-23 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7592336B2
(en)
|
2005-05-10 |
2009-09-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7569600B2
(en)
|
2005-05-13 |
2009-08-04 |
Virochem Pharma Inc. |
Compounds and methods for the treatment of prevention of Flavivirus infections
|
EP1881828A4
(en)
*
|
2005-05-20 |
2009-06-03 |
Valeant Res & Dev |
TREATMENT OF HEPATITIS C (HCV) USING SUB-THERAPEUTIC DOSES OF RIBAVIRIN
|
US20070237818A1
(en)
*
|
2005-06-02 |
2007-10-11 |
Malcolm Bruce A |
Controlled-release formulation of HCV protease inhibitor and methods using the same
|
WO2006130628A2
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Combination of hcv protease inhibitors with a surfactant
|
US20060276404A1
(en)
*
|
2005-06-02 |
2006-12-07 |
Anima Ghosal |
Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
|
WO2006130686A2
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Hcv protease inhibitors in combination with food
|
AR054778A1
(es)
|
2005-06-17 |
2007-07-18 |
Novartis Ag |
Uso de sangliferina en hcv
|
US7608592B2
(en)
*
|
2005-06-30 |
2009-10-27 |
Virobay, Inc. |
HCV inhibitors
|
US7601686B2
(en)
|
2005-07-11 |
2009-10-13 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2007015824A2
(en)
|
2005-07-25 |
2007-02-08 |
Intermune, Inc. |
Novel macrocyclic inhibitors of hepatitis c virus replication
|
US7666834B2
(en)
|
2005-07-29 |
2010-02-23 |
Tibotec Pharmaceuticals Ltd. |
Macrocyclic inhibitors of hepatitis C virus
|
PE20070211A1
(es)
*
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
PE20070210A1
(es)
|
2005-07-29 |
2007-04-16 |
Tibotec Pharm Ltd |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
DE602006019741D1
(de)
|
2005-07-29 |
2011-03-03 |
Medivir Ab |
Makrocyclische inhibitoren des hepatitis-c-virus
|
TWI393723B
(zh)
|
2005-07-29 |
2013-04-21 |
Tibotec Pharm Ltd |
C型肝炎病毒之大環抑制劑(九)
|
WO2007014920A1
(en)
|
2005-07-29 |
2007-02-08 |
Tibotec Pharmaceuticals Ltd. |
Macrocyclic inhibitors of hepatitis c virus
|
ME01318B
(me)
|
2005-07-29 |
2013-12-20 |
Tibotec Pharm Ltd |
Makrociklički inhibitori virusa hepatitisa C
|
PL1913015T3
(pl)
|
2005-07-29 |
2014-04-30 |
Janssen R&D Ireland |
Makrocykliczne inhibitory wirusa zapalenia wątroby typu C
|
JO2768B1
(en)
|
2005-07-29 |
2014-03-15 |
تيبوتيك فارماسيوتيكالز ليمتد |
Large cyclic inhibitors of hepatitis C virus
|
US20090325889A1
(en)
*
|
2005-08-01 |
2009-12-31 |
David Alan Campbell |
Hepatitis c serine protease inhibitors and uses therefor
|
MX2008001528A
(es)
|
2005-08-02 |
2008-04-04 |
Vertex Pharma |
Inhibidores de serina proteasas.
|
ES2344156T3
(es)
|
2005-08-19 |
2010-08-19 |
Vertex Pharmaceuticals Incorporated |
Procedimientos e intermedios.
|
US8399615B2
(en)
|
2005-08-19 |
2013-03-19 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates
|
US7964624B1
(en)
|
2005-08-26 |
2011-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
AR055395A1
(es)
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
US20090099186A1
(en)
*
|
2005-10-11 |
2009-04-16 |
Leonid Beigelman |
Inhibitors of viral replication
|
KR20080056295A
(ko)
|
2005-10-11 |
2008-06-20 |
인터뮨, 인크. |
C형 간염 바이러스 복제를 억제하기 위한 화합물 및 방법
|
US7772183B2
(en)
|
2005-10-12 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7741281B2
(en)
|
2005-11-03 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP1948678B1
(en)
|
2005-11-09 |
2013-05-01 |
Onyx Therapeutics, Inc. |
Compounds for enzyme inhibition
|
US7705138B2
(en)
|
2005-11-11 |
2010-04-27 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
EP2392588A3
(en)
|
2005-11-11 |
2012-03-07 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
PT1966130E
(pt)
|
2005-12-23 |
2014-01-30 |
Zealand Pharma As |
Compostos miméticos de lisina modificados
|
EP2029153A2
(en)
*
|
2006-01-27 |
2009-03-04 |
Phenomix Corporation |
Hepatitis c serine protease inhibitors and uses therefor
|
CA2641859A1
(en)
*
|
2006-02-09 |
2007-08-16 |
Schering Corporation |
Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto
|
JP5436864B2
(ja)
|
2006-02-27 |
2014-03-05 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Vx−950を含む共結晶体およびそれを含む医薬組成物
|
WO2007109080A2
(en)
*
|
2006-03-16 |
2007-09-27 |
Vertex Pharmaceuticals Incorporated |
Deuterated hepatitis c protease inhibitors
|
BRPI0710878A2
(pt)
|
2006-04-11 |
2015-03-31 |
Novartis Ag |
Compostos orgânicos e seus usos
|
US8017612B2
(en)
|
2006-04-18 |
2011-09-13 |
Japan Tobacco Inc. |
Piperazine compound and use thereof as a HCV polymerase inhibitor
|
RU2419626C2
(ru)
|
2006-05-23 |
2011-05-27 |
Айрм Ллк |
Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
|
MY183014A
(en)
|
2006-06-19 |
2021-02-05 |
Onyx Therapeutics Inc |
Compounds for enzyme inhibition
|
EP2049474B1
(en)
|
2006-07-11 |
2015-11-04 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
KR20090057035A
(ko)
*
|
2006-08-21 |
2009-06-03 |
유나이티드 세러퓨틱스 코오포레이션 |
바이러스 감염의 치료를 위한 병용 요법
|
AU2007290535A1
(en)
*
|
2006-08-28 |
2008-03-06 |
Vertex Pharmaceuticals Incorporated |
Method for identifying protease inhibitors
|
US8343477B2
(en)
|
2006-11-01 |
2013-01-01 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
US7772180B2
(en)
|
2006-11-09 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
AU2007321677B2
(en)
|
2006-11-15 |
2013-04-11 |
Vertex Pharmaceuticals (Canada) Incorporated |
Thiophene analogues for the treatment or prevention of flavivirus infections
|
US7888464B2
(en)
|
2006-11-16 |
2011-02-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8003604B2
(en)
|
2006-11-16 |
2011-08-23 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7763584B2
(en)
|
2006-11-16 |
2010-07-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2099430A2
(en)
|
2006-12-07 |
2009-09-16 |
Schering Corporation |
Ph sensitive matrix formulation
|
EP2468724B1
(en)
|
2006-12-21 |
2015-11-18 |
Zealand Pharma A/S |
Synthesis of pyrrolidine compounds
|
CA2674831A1
(en)
|
2006-12-22 |
2008-11-13 |
Schering Corporation |
5,6-ring annulated indole derivatives and methods of use thereof
|
MX2009006878A
(es)
|
2006-12-22 |
2009-07-07 |
Schering Corp |
Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas.
|
CN101631773A
(zh)
|
2006-12-22 |
2010-01-20 |
先灵公司 |
治疗或预防hcv和相关病毒感染的4,5-环化吲哚衍生物
|
JP5554569B2
(ja)
|
2007-02-08 |
2014-07-23 |
ヤンセン・アールアンドデイ・アイルランド |
ピリミジン置換された大環状hcv阻害剤
|
WO2008097676A1
(en)
*
|
2007-02-09 |
2008-08-14 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
EP2134717A2
(en)
|
2007-02-27 |
2009-12-23 |
Vertex Pharmceuticals Incorporated |
Inhibitors of serine proteases
|
PT2114924E
(pt)
*
|
2007-02-27 |
2012-04-03 |
Vertex Pharma |
Co-cristais e composições farmacêuticas que compreendem os mesmos
|
CA2696053A1
(en)
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of liver diseases
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
MX2009011930A
(es)
|
2007-05-04 |
2009-11-18 |
Vertex Pharma |
Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c.
|
BRPI0813733A2
(pt)
|
2007-06-29 |
2019-11-05 |
Gilead Sciences Inc |
composto com atividade inibidora de hcv, sua composição farmacêutica e seu uso.
|
WO2009005676A2
(en)
|
2007-06-29 |
2009-01-08 |
Gilead Sciences, Inc. |
Antiviral compounds
|
CA2697454C
(en)
|
2007-08-29 |
2015-11-03 |
Schering Corporation |
2-carboxy substituted indole derivatives and methods of use thereof
|
MX2010002319A
(es)
|
2007-08-29 |
2010-03-22 |
Schering Corp |
Derivados indolicos 2,3 sustituidos para el tratamiento de infecciones virales.
|
EP2195317B1
(en)
|
2007-08-29 |
2012-01-18 |
Schering Corporation |
2,3-substituted azaindole derivatives for treating viral infections
|
EP2185546B1
(en)
*
|
2007-08-30 |
2011-10-26 |
Vertex Pharmceuticals Incorporated |
Co-crystals and pharmaceutical compositions comprising the same
|
GB0718575D0
(en)
|
2007-09-24 |
2007-10-31 |
Angeletti P Ist Richerche Bio |
Nucleoside derivatives as inhibitors of viral polymerases
|
NZ584814A
(en)
|
2007-10-04 |
2012-03-30 |
Onyx Therapeutics Inc |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
EP2222660B1
(en)
|
2007-11-16 |
2014-03-26 |
Merck Sharp & Dohme Corp. |
3-heterocyclic substituted indole derivatives and methods of use thereof
|
US8377928B2
(en)
|
2007-11-16 |
2013-02-19 |
Merck Sharp & Dohme Corp. |
3-aminosulfonyl substituted indole derivatives and methods of use thereof
|
US8202996B2
(en)
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
AU2009210789B2
(en)
|
2008-02-04 |
2014-01-30 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
US8163921B2
(en)
|
2008-04-16 |
2012-04-24 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7964560B2
(en)
|
2008-05-29 |
2011-06-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2300491B1
(en)
|
2008-05-29 |
2016-01-06 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
CA2727620A1
(en)
|
2008-06-13 |
2009-12-17 |
Schering Corporation |
Tricyclic indole derivatives and methods of use thereof
|
EP2476690A1
(en)
|
2008-07-02 |
2012-07-18 |
IDENIX Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
TWI409265B
(zh)
|
2008-08-20 |
2013-09-21 |
Merck Sharp & Dohme |
經取代之吡啶及嘧啶衍生物及彼等於治療病毒感染之用途
|
US8470834B2
(en)
|
2008-08-20 |
2013-06-25 |
Merck Sharp & Dohme Corp. |
AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
CA2734487A1
(en)
|
2008-08-20 |
2010-02-25 |
Southern Research Institute |
Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
ES2439009T3
(es)
|
2008-08-20 |
2014-01-21 |
Merck Sharp & Dohme Corp. |
Derivados de piridina y pirimidina sustituidos con etenilo y su uso en el tratamiento de infecciones virales
|
US8207341B2
(en)
|
2008-09-04 |
2012-06-26 |
Bristol-Myers Squibb Company |
Process or synthesizing substituted isoquinolines
|
US8044087B2
(en)
|
2008-09-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8563505B2
(en)
|
2008-09-29 |
2013-10-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2341924A4
(en)
|
2008-10-02 |
2013-01-23 |
David Gladstone Inst |
METHOD FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
|
MX2011004225A
(es)
|
2008-10-21 |
2011-06-21 |
Onyx Therapeutics Inc |
Terapia de combinacion con epoxicetonas peptidicas.
|
WO2010065668A1
(en)
|
2008-12-03 |
2010-06-10 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hcv ns5a
|
PE20150939A1
(es)
|
2008-12-03 |
2015-07-19 |
Presidio Pharmaceuticals Inc |
Inhibidores de la proteina no estructural 5a del virus de la hepatitis c
|
US8283310B2
(en)
|
2008-12-15 |
2012-10-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8914351B2
(en)
|
2008-12-16 |
2014-12-16 |
Clinton A. Krislov |
Method and system for secure automated document registration from social media networks
|
US8589372B2
(en)
|
2008-12-16 |
2013-11-19 |
Clinton A. Krislov |
Method and system for automated document registration with cloud computing
|
WO2010080389A1
(en)
*
|
2008-12-19 |
2010-07-15 |
Gilead Sciences, Inc. |
Hcv ns3 protease inhibitors
|
JP5713919B2
(ja)
|
2008-12-23 |
2015-05-07 |
ギリアド ファーマセット エルエルシー |
ヌクレオシドホスホラミデート
|
PA8855701A1
(es)
|
2008-12-23 |
2010-07-27 |
|
Análogos de nucleósidos
|
CL2009002206A1
(es)
|
2008-12-23 |
2011-08-26 |
Gilead Pharmasset Llc |
Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
|
US8102720B2
(en)
*
|
2009-02-02 |
2012-01-24 |
Qualcomm Incorporated |
System and method of pulse generation
|
WO2010101967A2
(en)
|
2009-03-04 |
2010-09-10 |
Idenix Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole hcv polymerase inhibitors
|
JP2012520884A
(ja)
|
2009-03-18 |
2012-09-10 |
ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー |
フラビウイルス科ウイルス感染症を治療する方法および組成物
|
TWI504598B
(zh)
|
2009-03-20 |
2015-10-21 |
Onyx Therapeutics Inc |
結晶性三肽環氧酮蛋白酶抑制劑
|
JP5735482B2
(ja)
|
2009-03-27 |
2015-06-17 |
プレシディオ ファーマシューティカルズ インコーポレイテッド |
縮合環のc型肝炎阻害剤
|
EP2416772A1
(en)
|
2009-04-06 |
2012-02-15 |
PTC Therapeutics, Inc. |
Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent
|
EP2416765B1
(en)
|
2009-04-06 |
2016-03-30 |
PTC Therapeutics, Inc. |
Hcv inhibitor and therapeutic agent combinations
|
TW201040181A
(en)
|
2009-04-08 |
2010-11-16 |
Idenix Pharmaceuticals Inc |
Macrocyclic serine protease inhibitors
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
TWI598358B
(zh)
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
US8980920B2
(en)
|
2009-05-29 |
2015-03-17 |
Merck Sharp & Dohme Corp. |
Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C
|
CA2769652A1
(en)
|
2009-08-05 |
2011-02-10 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
|
HRP20161025T1
(hr)
|
2009-09-15 |
2016-11-04 |
Taigen Biotechnology Co., Ltd. |
Inhibitori proteaze hcv-a
|
US8853147B2
(en)
|
2009-11-13 |
2014-10-07 |
Onyx Therapeutics, Inc. |
Use of peptide epoxyketones for metastasis suppression
|
US20110117055A1
(en)
|
2009-11-19 |
2011-05-19 |
Macdonald James E |
Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
|
CA2781614A1
(en)
|
2009-11-25 |
2011-06-09 |
Vertex Pharmaceuticals Incorporated |
5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
|
WO2011066241A1
(en)
|
2009-11-25 |
2011-06-03 |
Schering Corporation |
Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
|
TW201136942A
(en)
|
2009-12-18 |
2011-11-01 |
Idenix Pharmaceuticals Inc |
5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
|
CA2785488A1
(en)
|
2009-12-22 |
2011-07-21 |
Merck Sharp & Dohme Corp. |
Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
|
MX2012007341A
(es)
|
2009-12-22 |
2012-07-20 |
Cephalon Inc |
Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
|
CN102883718A
(zh)
|
2009-12-24 |
2013-01-16 |
顶点制药公司 |
用于治疗或预防黄病毒感染的类似物
|
BR112012018897A2
(pt)
|
2010-01-27 |
2017-10-03 |
Ab Pharma Ltd |
Compostos poli-heterocíclicos altamente potentes como inibidores de hcv
|
EP2536410B1
(en)
|
2010-02-18 |
2015-09-23 |
Merck Sharp & Dohme Corp. |
Substituted pyrimidine derivatives and their use in treating viral infections
|
BR112012022060A2
(pt)
|
2010-03-01 |
2018-05-08 |
Onyx Therapeutics Inc |
composto para a inibição de imunoproteassoma
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
AU2011224698A1
(en)
|
2010-03-09 |
2012-11-01 |
Merck Sharp & Dohme Corp. |
Fused Tricyclic Silyl Compounds and methods of use thereof for the treatment of viral diseases
|
MX2012010919A
(es)
|
2010-03-24 |
2013-02-01 |
Vertex Pharma |
Analogos para el tratamiento o prevencion de infecciones por flavivirus.
|
JP2013522375A
(ja)
|
2010-03-24 |
2013-06-13 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス感染を処置または予防するためのアナログ
|
TW201141857A
(en)
|
2010-03-24 |
2011-12-01 |
Vertex Pharma |
Analogues for the treatment or prevention of flavivirus infections
|
WO2011119858A1
(en)
|
2010-03-24 |
2011-09-29 |
Vertex Pharmaceuticals Incorporated |
Analogues for the treatment or prevention of flavivirus infections
|
TW201139457A
(en)
|
2010-03-31 |
2011-11-16 |
Pharmasset Inc |
Stereoselective synthesis of phosphorus containing actives
|
BR112012024661A2
(pt)
|
2010-04-01 |
2015-09-15 |
Centre Nat Rech Scient |
composto, composição farmacêutica e método de tratamento de um hospedeiro infectado com vírus de hepatite c
|
US8697646B2
(en)
|
2010-04-07 |
2014-04-15 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxyketone immunoproteasome inhibitor
|
WO2011149856A1
(en)
|
2010-05-24 |
2011-12-01 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hcv ns5a
|
WO2011156545A1
(en)
|
2010-06-09 |
2011-12-15 |
Vertex Pharmaceuticals Incorporated |
Viral dynamic model for hcv combination therapy
|
EP2582717A2
(en)
|
2010-06-15 |
2013-04-24 |
Vertex Pharmaceuticals Incorporated |
Hcv ns5b polymerase mutants
|
MX2012014918A
(es)
|
2010-06-28 |
2013-04-08 |
Vertex Pharma |
Compuestos y metodos para tratamiento o prevencion de infecciones por flavivirus.
|
EP2585448A1
(en)
|
2010-06-28 |
2013-05-01 |
Vertex Pharmaceuticals Incorporated |
Compounds and methods for the treatment or prevention of flavivirus infections
|
WO2012006070A1
(en)
|
2010-06-28 |
2012-01-12 |
Vertex Pharmaceuticals Incorporated |
Compounds and methods for the treatment or prevention of flavivirus infections
|
AU2011286276A1
(en)
|
2010-07-26 |
2013-01-24 |
Merck Sharp & Dohme Corp. |
Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
|
WO2012020036A1
(en)
|
2010-08-13 |
2012-02-16 |
F. Hoffmann-La Roche Ag |
Hepatitis c virus inhibitors
|
MX2013001869A
(es)
|
2010-08-17 |
2013-06-28 |
Vertex Pharma |
Compuestos y metodos para el tratamiento o prevencion de infecciones virales por flaviviridae.
|
CA2812779A1
(en)
|
2010-09-29 |
2012-04-19 |
Merck Sharp & Dohme Corp. |
Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
|
BR112013008510A2
(pt)
|
2010-10-08 |
2016-07-05 |
Novartis Ag |
vitamina e formulações de inibidores de sulfamida ns3
|
WO2012061248A2
(en)
|
2010-11-01 |
2012-05-10 |
Rfs Pharma, Llc |
Novel specific hcv ns3 protease inhibitors
|
EP3042910B1
(en)
|
2010-11-30 |
2019-01-09 |
Gilead Pharmasset LLC |
2'-spiro-nucleosides for use in the therapy of hepatitis c
|
WO2012109398A1
(en)
|
2011-02-10 |
2012-08-16 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
WO2012123298A1
(en)
|
2011-03-11 |
2012-09-20 |
F. Hoffmann-La Roche Ag |
Antiviral compounds
|
WO2012154321A1
(en)
|
2011-03-31 |
2012-11-15 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
EP2697242B1
(en)
|
2011-04-13 |
2018-10-03 |
Merck Sharp & Dohme Corp. |
2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
US8957203B2
(en)
|
2011-05-05 |
2015-02-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US10501493B2
(en)
|
2011-05-27 |
2019-12-10 |
Rqx Pharmaceuticals, Inc. |
Broad spectrum antibiotics
|
US8691757B2
(en)
|
2011-06-15 |
2014-04-08 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2857705A1
(en)
|
2011-06-16 |
2012-12-20 |
AB Pharma Ltd. |
Macrocyclic heterocyclic compounds for inhibiting hepatitis c virus and preparation and use thereof
|
CN103732242A
(zh)
|
2011-06-23 |
2014-04-16 |
迪格纳生物技术公司 |
用与IFN-α2b组合的IFN-α5在患者群体中治疗慢性丙型肝炎
|
WO2012175581A1
(en)
|
2011-06-24 |
2012-12-27 |
F. Hoffmann-La Roche Ag |
Antiviral compounds
|
CN102807607B
(zh)
*
|
2011-07-22 |
2013-10-23 |
爱博新药研发(上海)有限公司 |
抑制丙肝病毒的稠环杂环类化合物、其中间体及其应用
|
WO2013016490A1
(en)
|
2011-07-26 |
2013-01-31 |
Vertex Pharmaceuticals Incorporated |
Thiophene compounds
|
WO2013016499A1
(en)
|
2011-07-26 |
2013-01-31 |
Vertex Pharmaceuticals Incorporated |
Methods for preparation of thiophene compounds
|
WO2013033901A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
|
WO2013033900A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
|
WO2013033899A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
|
WO2013039920A1
(en)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
CA2847892A1
(en)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US20140378416A1
(en)
|
2011-09-14 |
2014-12-25 |
Michael P. Dwyer |
Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
|
KR101621181B1
(ko)
|
2011-10-10 |
2016-05-13 |
에프. 호프만-라 로슈 아게 |
항바이러스성 화합물
|
US8507460B2
(en)
|
2011-10-14 |
2013-08-13 |
Idenix Pharmaceuticals, Inc. |
Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
WO2013072328A1
(en)
|
2011-11-14 |
2013-05-23 |
Sanofi |
Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
ES3018133T3
(en)
|
2011-11-30 |
2025-05-14 |
Univ Emory |
Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
|
WO2013086133A1
(en)
|
2011-12-06 |
2013-06-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for treating viral diseases
|
KR20140104030A
(ko)
|
2011-12-16 |
2014-08-27 |
에프. 호프만-라 로슈 아게 |
Hcv ns5a의 억제제
|
CN104011060A
(zh)
|
2011-12-20 |
2014-08-27 |
弗·哈夫曼-拉罗切有限公司 |
作为hcv rna复制抑制剂的4‘-叠氮基,3’-氟取代的核苷衍生物
|
MY171577A
(en)
|
2011-12-20 |
2019-10-21 |
Hoffmann La Roche |
2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
|
US8809354B2
(en)
|
2011-12-31 |
2014-08-19 |
Sheikh Riazuddin |
3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
|
CA2858814A1
(en)
|
2012-01-12 |
2013-07-18 |
Rfs Pharma, Llc |
Hcv ns3 protease inhibitors
|
WO2013133927A1
(en)
|
2012-02-13 |
2013-09-12 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate]
|
CN104254518A
(zh)
*
|
2012-02-16 |
2014-12-31 |
阿奇克斯制药公司 |
线性肽抗生素
|
CA2857262A1
(en)
*
|
2012-02-24 |
2013-08-29 |
F. Hoffmann-La Roche Ag |
Antiviral compounds
|
EP2827876A4
(en)
|
2012-03-22 |
2015-10-28 |
Alios Biopharma Inc |
PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
|
EP2852604B1
(en)
|
2012-05-22 |
2017-04-12 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
US9296778B2
(en)
|
2012-05-22 |
2016-03-29 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphate prodrugs for HCV infection
|
JP6165848B2
(ja)
|
2012-05-22 |
2017-07-19 |
イデニク ファーマシューティカルズ エルエルシー |
肝疾患のためのd−アミノ酸化合物
|
US20140010783A1
(en)
|
2012-07-06 |
2014-01-09 |
Hoffmann-La Roche Inc. |
Antiviral compounds
|
TW201414751A
(zh)
|
2012-07-09 |
2014-04-16 |
歐尼克斯治療公司 |
肽環氧酮蛋白酶抑制劑之前驅藥物
|
WO2014053533A1
(en)
|
2012-10-05 |
2014-04-10 |
Sanofi |
Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
|
MX353422B
(es)
|
2012-10-08 |
2018-01-12 |
Idenix Pharmaceuticals Llc |
Análogos de 2'-cloronucleósido para infección por vhc.
|
US20140112886A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
RS55592B1
(sr)
|
2012-10-19 |
2017-06-30 |
Bristol Myers Squibb Co |
9-metil supstituisani heksadekahidrociklopropa(e)pirolo(1,2-a)(1,4)diazaciklopentadecinil karbamat derivati kao nestrukturalni 3 (ns3) proteazni inhibitori za lečenje infekcijavirusom hepatitisa c
|
EP2909222B1
(en)
|
2012-10-22 |
2021-05-26 |
Idenix Pharmaceuticals LLC |
2',4'-bridged nucleosides for hcv infection
|
US10260089B2
(en)
|
2012-10-29 |
2019-04-16 |
The Research Foundation Of The State University Of New York |
Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
|
US9598433B2
(en)
|
2012-11-02 |
2017-03-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2014071007A1
(en)
|
2012-11-02 |
2014-05-08 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
US9643999B2
(en)
|
2012-11-02 |
2017-05-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2014070974A1
(en)
|
2012-11-05 |
2014-05-08 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
WO2014078436A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
WO2014099941A1
(en)
|
2012-12-19 |
2014-06-26 |
Idenix Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
BR112015017414A2
(pt)
|
2013-01-23 |
2017-07-11 |
Hoffmann La Roche |
derivados de triazol antivirais
|
TW201526899A
(zh)
|
2013-02-28 |
2015-07-16 |
Alios Biopharma Inc |
醫藥組成物
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
EP2964637B1
(en)
|
2013-03-05 |
2017-04-12 |
F. Hoffmann-La Roche AG |
Antiviral compounds
|
WO2014137869A1
(en)
|
2013-03-07 |
2014-09-12 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
EP2981542B1
(en)
|
2013-04-01 |
2021-09-15 |
Idenix Pharmaceuticals LLC |
2',4'-fluoro nucleosides for the treatment of hcv
|
US20180200280A1
(en)
|
2013-05-16 |
2018-07-19 |
Riboscience Llc |
4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
|
CA2912682C
(en)
|
2013-05-16 |
2021-07-06 |
Riboscience Llc |
4'-fluoro-2'-methyl substituted nucleoside derivatives
|
SG11201509427RA
(en)
|
2013-05-16 |
2015-12-30 |
Riboscience Llc |
4'-azido, 3'-deoxy-3'-fluoro substituted nucleoside derivatives
|
EP3004130B1
(en)
|
2013-06-05 |
2019-08-07 |
Idenix Pharmaceuticals LLC. |
1',4'-thio nucleosides for the treatment of hcv
|
WO2015017713A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
CN105636978A
(zh)
*
|
2013-08-14 |
2016-06-01 |
阿奇克斯制药公司 |
线性肽抗生素
|
KR102239196B1
(ko)
|
2013-08-27 |
2021-04-12 |
길리애드 파마셋 엘엘씨 |
2종의 항바이러스 화합물의 조합 제제
|
EP3046924A1
(en)
|
2013-09-20 |
2016-07-27 |
IDENIX Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
EP3063140A4
(en)
|
2013-10-30 |
2017-11-08 |
Merck Sharp & Dohme Corp. |
Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
|
US20160271162A1
(en)
|
2013-11-01 |
2016-09-22 |
Idenix Pharmacueticals, Llc |
D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
|
US20170198005A1
(en)
|
2013-11-27 |
2017-07-13 |
Idenix Pharmaceuticals Llc |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
WO2015095419A1
(en)
|
2013-12-18 |
2015-06-25 |
Idenix Pharmaceuticals, Inc. |
4'-or nucleosides for the treatment of hcv
|
EP2899207A1
(en)
|
2014-01-28 |
2015-07-29 |
Amikana.Biologics |
New method for testing HCV protease inhibition
|
WO2015134561A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
WO2015134560A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
EP3113763A1
(en)
|
2014-03-05 |
2017-01-11 |
Idenix Pharmaceuticals LLC |
Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
|
EP3131914B1
(en)
|
2014-04-16 |
2023-05-10 |
Idenix Pharmaceuticals LLC |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
US11072635B2
(en)
|
2015-11-20 |
2021-07-27 |
Rqx Pharmaceuticals, Inc. |
Macrocyclic broad spectrum antibiotics
|
US10526315B2
(en)
|
2016-06-21 |
2020-01-07 |
Orion Ophthalmology LLC |
Carbocyclic prolinamide derivatives
|
KR102512201B1
(ko)
|
2016-06-21 |
2023-03-20 |
오리온 옵탈몰로지 엘엘씨 |
지방족 프롤린아미드 유도체
|
EP3472149B1
(en)
|
2016-06-21 |
2023-08-30 |
Orion Ophthalmology LLC |
Heterocyclic prolinamide derivatives
|
CN109661389A
(zh)
*
|
2016-08-23 |
2019-04-19 |
豪夫迈·罗氏有限公司 |
作为htra1抑制剂的新型二氟酮酰胺衍生物
|
WO2018202865A1
(en)
|
2017-05-05 |
2018-11-08 |
Zealand Pharma A/S |
Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
|
GB2563396B
(en)
*
|
2017-06-12 |
2020-09-23 |
Ustav Organicke Chemie A Biochemie Av Cr V V I |
Inhibitors of Rhomboid Intramembrane Proteases
|
EP3684374B1
(en)
|
2017-09-21 |
2025-07-30 |
Riboscience LLC |
4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
|
EP3891508A1
(en)
|
2018-12-04 |
2021-10-13 |
Bristol-Myers Squibb Company |
Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
|
US11208387B2
(en)
|
2019-05-28 |
2021-12-28 |
Genentech, Inc. |
Macrocyclic broad spectrum antibiotics
|